Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.

Therapeutic Advances in Medical Oncology
Anastasios GkountakosEmilio Bria

Abstract

The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint axis, which were initially considered as a late-line treatment option, gradually became the standard of care as first-line treatment for subgroups of NSCLC patients. However, a significant fraction of patients either fails to respond or progresses after a partial response to ICI treatment. Thus, the identification of mechanisms responsible for innate and acquired resistance to immunotherapy within a rapidly evolving tumor microenvironment (TME) is urgently required, as is the identification of reliable predictive biomarkers beyond PD-L1 expression. The deregulation of the epigenome is a key driver of cancer initiation and progression, and it has also been shown to drive therapeutic resistance. Tumor education of infiltrating myeloid cells towards an immuno-suppressive phenotype as well as induction of T-cell dysfunction in the TME is also driven by epigenome reprogramming. As it stands and, given their dynamic nature, epigeneti...Continue Reading

References

Oct 29, 2013·Oncotarget·John WrangleStephen B Baylin
May 13, 2014·Journal of Molecular Cell Biology·Matjaz RokavecHeiko Hermeking
Aug 21, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisUNKNOWN WHO Panel
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Nov 19, 2015·Journal of the National Cancer Institute·Maria Angelica CortezJames W Welsh
Mar 12, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hong ZhengAmer A Beg
Mar 24, 2016·Journal of Clinical Medicine·Kentaro Inamura, Yuichi Ishikawa
Jul 20, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Peter J Chockley, Venkateshwar G Keshamouni
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Mar 21, 2017·Handbook of Experimental Pharmacology·Rodrigo N RamosEmanuela Romano
May 10, 2017·Journal of Hematology & Oncology·Sachin Gopalkrishna PaiFrancis Joseph Giles
Sep 19, 2017·Seminars in Cancer Biology·Michaël Duruisseaux, Manel Esteller
Nov 9, 2017·Annals of Translational Medicine·Niki KarachaliouRafael Rosell
Nov 10, 2017·Blood·Behzad RowshanravanDavid M Sansom
Nov 28, 2017·Cancer Cell International·Laura BoldriniGabriella Fontanini
Jan 28, 2016·Signal Transduction and Targeted Therapy·Yong Peng, Carlo M Croce
Mar 22, 2018·Immunity·Chong SunTon N Schumacher
Apr 5, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wei-Bin XieYun-Hui Li
May 5, 2018·International Journal of Biological Sciences·Junmi LuSongqing Fan
Jul 25, 2018·Annals of Surgical Oncology·Toan PhamRobert Ramsay
Aug 3, 2018·Annals of Translational Medicine·Marios A DiamantopoulosAndreas Scorilas
Nov 18, 2018·Frontiers in Immunology·Ning YangJingtao Chen
Jan 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mattia BoeriGabriella Sozzi
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer
Jan 18, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Benjamin P LevyLuis Paz-Ares
Feb 14, 2019·Nature Reviews. Cancer·Jonathan J HavelTimothy A Chan
Mar 16, 2019·Frontiers in Immunology·Anna E Vilgelm, Ann Richmond
Apr 28, 2019·Journal of Biomedical Science·Chun-Ying Yu, Hung-Chih Kuo
Jul 28, 2019·Journal for Immunotherapy of Cancer·Liangliang CaiJie Wang
Aug 10, 2019·Nature Reviews. Genetics·Lasse S KristensenJørgen Kjems
Aug 15, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jhanelle E GrayAmer A Beg
Nov 14, 2019·Cancer Immunology, Immunotherapy : CII·Tyler R McCawTroy D Randall
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 18, 2020·Cell Death & Disease·JunFeng WangShiDong Xu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.